Traditional Chinese medicine composition for improving or treating dilated cardiomyopathy and application thereof

Through traditional Chinese medicine compositions of Astragalus, Salvia miltiorrhiza, Heishun Tablets, Motherwort, Cohoma, and Licorice, clear heat and detoxify, promote serum and promote diuresis and reduce swelling, solve the problem of failure to effectively detoxify and target heart failure poison evil in the prior art. , significantly improve cardiac function and heart failure symptoms, and realize effective treatment of dilated cardiomyopathy.

CN118924812AActive Publication Date: 2024-11-12GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411331966.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-24
Publication Date
2024-11-12
Estimated Expiration
2044-09-24

AI Technical Summary

Technical Problem

The existing traditional Chinese medicines for dilated cardiomyopathy have not been effectively detoxified and targeted the "stasis" and "water" poisonous evils in heart failure, and the efficacy is not ideal, especially in chronic heart failure.

Method used

Using traditional Chinese medicine compositions of Astragalus, Salvia miltiorrhiza, Heishun Tablets, Motherwort, Cohoma, and Roasted Licorice, improve cardiac function, improve heart microcirculation, and relieve heart failure symptoms through the overall regulatory effect of clearing heat and detoxifying, promoting serum and promoting diuresis, promoting diuresis and reducing swelling. , delay the progression of heart failure and improve immunity.

Benefits of technology

Significantly improve heart function, relieve the symptoms of heart failure, delay the progress of heart failure, improve the quality of life, and have no toxic side effects at the moment, which is especially effective for patients with heart failure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924812A_ABST
    Figure CN118924812A_ABST
Patent Text Reader

Abstract

The invention relates to a traditional Chinese medicine composition for improving or treating dilated cardiomyopathy and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials: astragalus membranaceus, salvia miltiorrhiza, black prepared common monkshood daughter root, motherwort, cimicifugae foetidae and honey-fried licorice root. The radix astragali and the radix salviae miltiorrhizae are monarch drugs for tonifying qi and activating blood, the radix aconiti carmichaeli has the effects of dispelling cold and dampness and tonifying fire and supporting yang, the motherwort herb and the rhizoma cimicifugae are combined for activating blood and clearing, inducing diuresis to alleviate edema and clearing away heat and toxic materials, and the honey-fried licorice root is used for harmonizing the medicines and neutralizing the toxicity of the radix
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for improving or treating dilated cardiomyopathy and an application thereof. Background Art

[0002] Dilated cardiomyopathy (DCM) is a complex cardiomyopathy caused by both genetic and non-genetic factors, characterized by dilation of the left ventricle, right ventricle or both ventricles and systolic dysfunction. DCM leads to decreased left ventricular systolic function, progressive heart failure, ventricular and supraventricular arrhythmias, conduction system abnormalities, thromboembolism and sudden death. DCM has a poor prognosis and a high mortality rate. The purpose of Western medicine treatment is to correct heart failure, arrhythmias, and prevent complications such as thromboembolism. Although it can control the patient's clinical symptoms, the effect is not ideal. Traditional Chinese medicine can alleviate the clinical symptoms of the disease and improve cardiac function and prognosis. (Tan Yuqing, Li Ying, Li Jun. Current status of clinical research on traditional Chinese medicine for dilated cardiomyopathy [J]. Chinese Journal of Traditional Chinese Medicine, 2019, 34(08): 3655-3657.) Many domestic doctors have proposed their own empirical prescriptions based on their clinical experience and understanding of dilated cardiomyopathy. Among them, Kangxian Yixin Prescription is a self-made prescription developed by Dr. Wang Zhentao of Henan Provincial Hospital of Traditional Chinese Medicine based on Shengxian Decoction and Buzhong Yiqi Decoction. It can reduce myocardial cell hypertrophy and myocardial tissue pathological damage in DCM rats. It is composed of 13 Chinese medicinal herbs: Astragalus, Codonopsis, Atractylodes, Poria, Salvia, Chuanxiong, Paeonia lactiflora, Leonurus, Zedoaria, Bupleurum, Cimicifuga, Platycodon grandiflorum, and Licorice. (Zeng Chuiyi, Wang Zhentao, Bian Rutao. Effects of Kangxian Yixin Formula on CaN / NFAT3 Signal Transduction Pathway in Myocardial Cells of Rats with Dilated Cardiomyopathy [J]. Chinese Journal of Traditional Chinese Medicine, 2022, 37(03): 1331-1335.) At present, these Chinese patent medicines and self-made prescriptions for the treatment of dilated cardiomyopathy are based on invigorating qi and activating blood circulation as the fundamental treatment method. Current studies have found that dilated cardiomyopathy heart failure is also closely related to viral pathogens, and the above-mentioned compound Chinese medicine does not emphasize its detoxification effect. At the same time, the original prescription Qishen Granule emphasizes the pathogenesis of "deficiency-stasis-toxicity", and invigorating the heart, detoxifying, and activating blood circulation and removing stasis are the main treatment methods, targeting the efficacy of chronic heart failure. However, because dilated cardiomyopathy heart failure is mainly caused by "stasis" and "water" toxic pathogens, the compound needs to be optimized. Summary of the invention

[0003] In view of the deficiencies of the prior art, the object of the present invention is to provide a Chinese medicine composition for improving or treating dilated cardiomyopathy and its application.

[0004] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0005] In a first aspect, the present invention provides a traditional Chinese medicine composition for improving or treating dilated cardiomyopathy, wherein the raw materials for preparing the traditional Chinese medicine composition include astragalus, salvia miltiorrhiza, Heishun Pian, motherwort, cimicifuga, and licorice.

[0006] The pharmaceutical composition of the present invention is a pure Chinese medicine preparation, which has the effects of clearing away heat and detoxifying, promoting blood circulation and promoting diuresis, and reducing swelling. It utilizes the overall regulating effect of the Chinese medicine compound to improve cardiac function, improve cardiac microcirculation, relieve the symptoms of dilated cardiomyopathy heart failure, delay the progression of dilated cardiomyopathy heart failure, improve the quality of life of dilated cardiomyopathy heart failure patients, and improve the body's immunity, and has no toxic side effects. The effect is particularly good for patients with dilated cardiomyopathy heart failure. Astragalus and Salvia miltiorrhiza are the main drugs for invigorating qi and promoting blood circulation, while Aconite dispels cold and dampness, and replenishes fire and assists yang. The combination of Leonurus japonicus and Cimicifuga heracleifolia can promote blood circulation and promote diuresis and reduce swelling, clear away heat and detoxify, while Radix Glycyrrhizae Preparata harmonizes various drugs and neutralizes the toxicity of Aconite herb.

[0007] Preferably, the raw materials for preparing the traditional Chinese medicine composition include, by mass, 28-32 parts of astragalus, 13-17 parts of salvia miltiorrhiza, 7-11 parts of Heishunpian, 28-32 parts of Leonurus japonicus, 8-12 parts of Cimicifuga heracleifolia, and 4-8 parts of Radix Glycyrrhizae Preparata.

[0008] The mass fraction of the astragalus can be selected from 28 parts, 28.5 parts, 29 parts, 29.5 parts, 30 parts, 30.5 parts, 31 parts, 31.5 parts, 32 parts, etc., the mass fraction of salvia miltiorrhiza can be selected from 13 parts, 13.5 parts, 14 parts, 14.5 parts, 15 parts, 15.5 parts, 16 parts, 16.5 parts, 17 parts, etc., the mass fraction of Heishun tablets can be selected from 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, etc., the mass fraction of Leonurus japonicus can be selected from 14 parts, 15.5 parts, 16 parts, 16.5 parts, 17 parts, etc. The weight of the above-mentioned parts can be 28 parts, 28.5 parts, 29 parts, 29.5 parts, 30 parts, 30.5 parts, 31 parts, 31.5 parts, 32 parts, etc. The weight of the Cimicifuga can be 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, etc. The weight of the Glycyrrhiza uralensis can be 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, etc. Other specific point values ​​within the above-mentioned numerical range can be selected, so they will not be described one by one here.

[0009] Preferably, the Chinese medicine composition is prepared by a method comprising the following steps: mixing the raw materials for preparation with water and boiling them, filtering, concentrating the filtrate, and drying.

[0010] Preferably, the decoction is performed 2-4 times and the decoction time is 50-70 minutes.

[0011] The number of decoctions can be selected as 2 times, 3 times, 4 times, etc., and the time can be selected as 50min, 52min, 54min, 56min, 58min, 60min, 62min, 64min, 66min, 68min, 70min, etc. Other specific point values ​​within the above numerical range can be selected, so they will not be elaborated here.

[0012] Preferably, the mass of the water is 7-9 times the mass of the raw material, for example, 7 times, 7.2 times, 7.4 times, 7.6 times, 7.8 times, 8 times, 8.2 times, 8.4 times, 8.6 times, 8.8 times, 9 times, etc. Other specific point values ​​within the above numerical range can be selected, and they will not be described here one by one.

[0013] Preferably, the concentration refers to concentrating the filtrate to a relative density of 2.7-2.8 at 60°C, for example, 2.7, 2.71, 2.72, 2.73, 2.74, 2.75, 2.76, 2.77, 2.78, 2.79, 2.8, etc. Other specific point values ​​within the above numerical range can be selected, and they will not be described one by one here.

[0014] In a second aspect, the present invention provides a use of the Chinese medicine composition for improving or treating dilated cardiomyopathy according to the first aspect in the preparation of a medicament for improving myocardial injury.

[0015] In a third aspect, the present invention provides a use of the Chinese medicine composition for improving or treating dilated cardiomyopathy according to the first aspect in the preparation of a medicament for improving or treating dilated cardiomyopathy.

[0016] In a fourth aspect, the present invention provides a use of the Chinese medicine composition for improving or treating dilated cardiomyopathy according to the first aspect in the preparation of a drug for improving myocardial cell viability.

[0017] In a fifth aspect, the present invention provides a use of the traditional Chinese medicine composition for improving or treating dilated cardiomyopathy according to the first aspect in the preparation of a cardiomyocyte activator.

[0018] Preferably, the dosage form of the drug includes tablets, pills, capsules, granules, granules, and oral liquids.

[0019] Preferably, the drug further comprises a pharmaceutically acceptable excipient.

[0020] Preferably, the auxiliary material comprises any one of an excipient, a diluent, a carrier, a flavoring agent, a binder or a filler, or a combination of at least two thereof.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The pharmaceutical composition of the present invention is a pure Chinese medicine preparation, which has the effects of clearing away heat and detoxifying, promoting blood circulation and promoting diuresis, and reducing swelling. It utilizes the overall regulating effect of the Chinese medicine compound to improve cardiac function, improve cardiac microcirculation, relieve the symptoms of dilated cardiomyopathy heart failure, delay the progression of dilated cardiomyopathy heart failure, improve the quality of life of dilated cardiomyopathy heart failure patients, and improve the body's immunity, and has no toxic side effects. The effect is particularly good for patients with dilated cardiomyopathy heart failure. Astragalus and Salvia miltiorrhiza are the main drugs for invigorating qi and promoting blood circulation, while Aconite dispels cold and dampness, and replenishes fire and assists yang. The combination of Leonurus japonicus and Cimicifuga heracleifolia can promote blood circulation and promote diuresis and reduce swelling, clear away heat and detoxify, while Radix Glycyrrhizae Preparata harmonizes various drugs and neutralizes the toxicity of Aconite herb. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1A is the expression level of LDH mRNA in mice of different treatment groups.

[0024] Figure 1B is the expression level of mTinn mRNA in mice of different treatment groups.

[0025] Figure 2 This is the result of doxorubicin-induced dilated heart dysfunction in mice.

[0026] Figure 3A is the expression level of left ventricular ejection fraction (LVEF) in mice under different treatment groups.

[0027] Figure 3B is the expression level of left ventricular fraction shortening (LVFS) in mice under different treatment groups.

[0028] Figure 3C is the expression level of end-systolic internal diameter (LVIDs) in mice of different treatment groups.

[0029] Figure 4 It is the result of the effect of doxorubicin on the cardiac tissue pathology of mice.

[0030] Figure 5 This is the effect of different doses of Leonurus japonicus on adriamycin-induced H9C2 cardiomyocyte injury. DETAILED DESCRIPTION

[0031] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0032] Example 1

[0033] The present embodiment provides a traditional Chinese medicine composition, wherein the raw materials for preparing the traditional Chinese medicine composition include 30 parts of astragalus, 15 parts of salvia miltiorrhiza, 9 parts of Heishun Pian, 30 parts of motherwort, 10 parts of cimicifuga, and 6 parts of roasted liquorice.

[0034] The preparation method is as follows: the raw material is mixed with 8 times the mass of water and boiled for 3 times, each time boiling for 1 hour, the filtrate is combined, concentrated at 60°C to a relative density of 2.7, and dried to obtain the product.

[0035] It is recorded as the expansion optimization method.

[0036] Example 2

[0037] The present embodiment provides a traditional Chinese medicine composition, wherein the raw materials for preparing the traditional Chinese medicine composition include 30 parts of astragalus, 15 parts of salvia miltiorrhiza, 9 parts of Heishun Pian, 20 parts of Leonurus japonicus, 10 parts of Cimicifuga heracleifolia, and 6 parts of Radix Glycyrrhizae Preparata.

[0038] The preparation method is similar to that of Example 1.

[0039] Example 3

[0040] The present embodiment provides a traditional Chinese medicine composition, wherein the raw materials for preparing the traditional Chinese medicine composition include 30 parts of astragalus, 15 parts of salvia miltiorrhiza, 9 parts of Heishun Pian, 10 parts of Leonurus japonicus, 10 parts of Cimicifuga heracleifolia, and 6 parts of Radix Glycyrrhizae Preparata.

[0041] The preparation method is similar to that of Example 1.

[0042] Comparative Example 1

[0043] This comparative example provides a traditional Chinese medicine composition, wherein the raw materials for preparing the traditional Chinese medicine composition include 30 parts of astragalus, 15 parts of salvia miltiorrhiza, 9 parts of Heishun Pian, 10 parts of Scrophularia, 10 parts of honeysuckle, and 6 parts of roasted liquorice.

[0044] The preparation method is as follows: the raw material is mixed with 8 times the mass of water and boiled for 3 times, each time boiling for 1 hour, the filtrate is combined, concentrated at 60°C to a relative density of 1.2, and dried to obtain the product.

[0045] It was recorded as the original formula group of Qishen Granules.

[0046] Comparative Example 2

[0047] This comparative example provides a traditional Chinese medicine composition, wherein the raw materials for preparing the traditional Chinese medicine composition include 30 parts of astragalus, 15 parts of salvia miltiorrhiza, 9 parts of Heishun Pian, 40 parts of Leonurus japonicus, and 6 parts of roasted liquorice.

[0048] The preparation method is similar to that of Example 1.

[0049] Comparative Example 3

[0050] This comparative example provides a traditional Chinese medicine composition, wherein the raw materials for preparing the traditional Chinese medicine composition include 30 parts of astragalus, 15 parts of salvia miltiorrhiza, 9 parts of Heishun Pian, 40 parts of Cimicifuga heracleifolia, and 6 parts of roasted liquorice.

[0051] The preparation method is similar to that of Example 1.

[0052] Test Example 1

[0053] 1. Materials

[0054] 1.1 Drug: Doxorubicin (provided by Shanghai Yuanye Biotechnology Co., Ltd.)

[0055] 1.2 Animals: Wild-type C57BL / 6 mice

[0056] 2. Methods and Results

[0057] 2.1 Effects on Dox-induced myocardial injury in mice

[0058] 54 male mice weighing 20-22 g were divided into 9 groups:

[0059] ①Control group: 10mL / kg normal saline;

[0060] ②Model group: DOX 5mg / kg;

[0061] ③ Pravastatin group: DOX 5mg / kg + pravastatin 40mg / kg;

[0062] ④ Low-dose group: DOX 5mg / kg + heart expansion optimization formula 6.5g / kg;

[0063] ⑤Medium-dose group: DOX 5mg / kg+Xin Kuan Optimization Formula 13g / kg;

[0064] ⑥High-dose group: DOX 5mg / kg+Xin Kuan Optimization Formula 26g / kg;

[0065] ⑦ Combination group: DOX 5 mg / kg + the composition of Comparative Example 2 26 g / kg;

[0066] ⑧ Combination group 2: DOX 5 mg / kg + the composition of comparative example 3 26 g / kg;

[0067] ⑨Original formula group: DOX 5mg / kg + Qishen granules original formula 10.4g / kg

[0068] DOX was injected into the tail vein every week for four consecutive weeks. After the model was established, the drug was given by gavage once a day for 30 consecutive days. Color Doppler ultrasound was measured after the last administration, and then the animals were fasted for 12 hours and decapitated. Heart tissues were taken to determine LDH and MT values.

[0069] The results are shown in Figure 1. It can be seen from the figure that compared with the normal control group, the LDH and mTinn values ​​of the model group were significantly increased (P < 0.01); compared with the model group, the LDH and mTinn values ​​of the pravastatin group were significantly decreased (P < 0.01); compared with the model group, the LDH and mTinn values ​​of the three dosage groups of the present invention were significantly decreased (P < 0.01), among which the high-dose group was the most obvious.

[0070] 2.2 Effects of Dox on Cardiac Function in Mice

[0071] Echocardiography is a test commonly used to evaluate heart function.

[0072] Test method: After 4 weeks of treatment, cardiac function was detected by ultrasound. Mice were anesthetized by inhalation of 1% isoflurane and fixed on the workbench in a supine position. The cardiac function of rats was detected by ultrasound. Transthoracic color Doppler ultrasound examination of each group of mice was performed. The left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), and left ventricular internal dimension-systole (LVIDs) were measured by ultrasound through the long axis section of the left heart through the sternum.

[0073] The results are as follows Figure 2 As shown in Figure 3, compared with the control group, the LVEF and LVFS levels of mice in the model group were significantly reduced, and the LVIDs level was significantly increased. Compared with the model group, the LVEF and LVFS levels of the original prescription group and the heart expansion group were increased, and the LVIDs level was reduced, among which the heart expansion group had the most obvious effect, and there was no significant change in the combination group 1 and the combination group 2.

[0074] 2.3 Effects of DOX on cardiac tissue pathology in mice

[0075] Test method: One day after ultrasound detection, mice were killed, the chest was opened to isolate the heart, and fixed with 4% paraformaldehyde for 24 hours. Routine dehydration and embedding were performed. HE staining was performed, and the heart tissue was observed under an optical microscope after sealing (Olympus, Japan). Finally, the inflammatory cell infiltration on the heart was qualitatively analyzed and the morphological changes were analyzed by blind reading and interpretation of the slides, and pictures were randomly taken in different fields of view.

[0076] The results are as follows Figure 4 As shown in the figure, the myocardial cells in the control group were evenly arranged and normal in morphology, and no abnormal morphological cells were observed. Compared with the control group, the myocardial cell structure and arrangement were disordered in the model group, and the intercellular gap was widened. Compared with the model group, the inflammatory cells in each drug-treated group were significantly reduced, and the myocardial cells were arranged more neatly. Compared with the pravastatin group, the inflammatory cells in the low-dose and medium-dose groups of the heart expansion optimization prescription increased, the myocardial structure was incomplete, and the degree of myocardial damage was severe; the inflammatory cells in the high-dose group of the heart expansion optimization prescription decreased, the cell boundaries were clearer, and the degree of myocardial damage was reduced.

[0077] 2.4 Effects of different doses of Leonurus japonicus in the optimized Qishen Granules heart-expanding formula on DOX-induced myocardial injury in H9C2 cells

[0078] In order to further prove the improvement effect of the optimized Qishen Granule Heart-expanding Formula on the myocardium, the CCK8 kit was used to evaluate the viability of DOX-induced H9C2 cardiomyocytes in an in vitro experiment.

[0079] Test method: CCK-8 method was used to detect cytotoxicity of cardiomyocytes. Cell suspension was prepared and cells in the logarithmic growth phase were taken at 1×10 4 The cells were inoculated in 96-well plates, and a normal control group, a model group and different concentrations of drugs were set up, and 3 replicates were set up for each group. After the cells adhered to the wall for 24 hours, the Chinese medicine composition described in Examples 1-3 (the amount of Leonurus japonicus added was 30 g, 20 g, and 10 g, respectively) was added to make the final concentration of the Chinese medicine composition 1600 μg / mL. After the drugs were intervened for 24 hours, 10 μL of CCK-8 solution was added to each well, the culture plate was incubated in an incubator for 1 hour, and the absorbance (A) value at 450 nm was measured with an enzyme marker.

[0080] Cell survival rate (%) = (A experimental well - A blank well) / (A control well - A blank well) × 100%

[0081] The results are as follows Figure 5 As shown, compared with the control group, the cell viability of the model group was significantly reduced. Compared with the model group, 30g of Leonurus herba in the optimized formula of Qishen Granule for expanding the heart was the best.

[0082] The applicant declares that the present invention illustrates a Chinese medicine composition for improving or treating dilated cardiomyopathy and its application through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0083] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0084] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A Chinese medicine composition for improving or treating dilated cardiomyopathy, It is characterized in that The raw materials for preparing the traditional Chinese medicine composition include astragalus, salvia miltiorrhiza, heishunpian, motherwort, cimicifuga and licorice.

2. The Chinese medicine composition for improving or treating dilated cardiomyopathy according to claim 1, It is characterized in that The raw materials for preparing the traditional Chinese medicine composition include, by weight, 28-32 parts of astragalus, 13-17 parts of salvia miltiorrhiza, 7-11 parts of Heishunpian, 28-32 parts of motherwort, 8-12 parts of cimicifuga, and 4-8 parts of licorice.

3. The Chinese medicine composition for improving or treating dilated cardiomyopathy according to claim 1 or 2, It is characterized in that The Chinese medicine composition is prepared by a method comprising the following steps: mixing the raw materials and water, decocting, filtering, concentrating the filtrate, and drying to obtain the composition.

4. The Chinese medicine composition for improving or treating dilated cardiomyopathy according to claim 3, It is characterized in that The decoction is performed 2-4 times and the decoction time is 50-70 minutes.

5. Use of the traditional Chinese medicine composition for improving or treating dilated cardiomyopathy according to any one of claims 1 to 4 in the preparation of a medicament for improving myocardial damage.

6. Use of the traditional Chinese medicine composition for improving or treating dilated cardiomyopathy according to any one of claims 1 to 4 in the preparation of a medicament for improving or treating dilated cardiomyopathy.

7. Use of the traditional Chinese medicine composition for improving or treating dilated cardiomyopathy according to any one of claims 1 to 4 in the preparation of a drug for improving myocardial cell viability.

8. Use of the traditional Chinese medicine composition for improving or treating dilated cardiomyopathy according to any one of claims 1 to 4 in the preparation of a myocardial cell activator.

9. The use according to any one of claims 5 to 8, It is characterized in that The dosage forms of the drug include tablets, pills, capsules, granules, granules, and oral liquids; Preferably, the drug further comprises a pharmaceutically acceptable excipient.

10. The use according to claim 9, It is characterized in that The auxiliary materials include any one of excipients, diluents, carriers, flavoring agents, adhesives or fillers, or a combination of at least two of them.

Citation Information

Patent Citations

  • A component-based traditional Chinese medicine for treating coronary heart disease and heart failure, and its preparation method.

    CN102258623A

  • Medicine for treating chronic cardiac failures and preparation method of medicine

    CN105012680A

  • Traditional Chinese medicine for treating dilated cardiomyopathy

    CN105055833A

  • Traditional Chinese medicine formula for treating chronic heart failure, preparation of traditional Chinese medicine formula and preparation method of preparation

    CN111110747A